BACKGROUND: Psychiatric comorbidity can adversely affect opioid dependence treatment outcomes. While the prevalence of psychiatric comorbidity among patients seeking methadone maintenance treatment has been documented, the extent to which these findings extend to patients seeking primary care office-based buprenorphine/naloxone treatment is unclear. AIMS: To determine the prevalence of mood and substance use disorders among patients seeking primary care office-based buprenorphine/naloxone treatment, via cross sectional survey. METHODS: 237 consecutive patients seeking primary care office-based buprenorphine/naloxone treatment were evaluated using modules from the Structured Clinical Interview for DSM-IV Axis I Disorders (SCID-I). Current (past 30 days) and past diagnoses were cataloged separately. RESULTS: Patients ranged in age from 18 to 62 years old (M=33.9, SD=9.9); 173 (73%) were men; 197 (83%) were white. Major depression was the most prevalent mood disorder (19% current, 24% past). A minority of patients met criteria for current dysthymia (6%), past mania (1%), or past hypomania (2%). While 37 patients (16%) met criteria for current abuse of or dependence on at least one non-opioid substance (7% cocaine, 4% alcohol, 4% cannabis, 2% sedatives, 0.4% stimulants, 0.4% polydrug), 168 patients (70%) percent met criteria for past abuse of or dependence on at least one non-opioid substance (43% alcohol, 38% cannabis, 30% cocaine, 9% sedatives, 8% hallucinogens, 4% stimulants, 1% polydrug, and 0.4% other substances). CONCLUSION: Mood and substance use comorbidity is prevalent among patients seeking primary care office-based buprenorphine/naloxone treatment. The findings support the need for clinicians to assess and address these conditions.
BACKGROUND:Psychiatric comorbidity can adversely affect opioid dependence treatment outcomes. While the prevalence of psychiatric comorbidity among patients seeking methadone maintenance treatment has been documented, the extent to which these findings extend to patients seeking primary care office-based buprenorphine/naloxone treatment is unclear. AIMS: To determine the prevalence of mood and substance use disorders among patients seeking primary care office-based buprenorphine/naloxone treatment, via cross sectional survey. METHODS: 237 consecutive patients seeking primary care office-based buprenorphine/naloxone treatment were evaluated using modules from the Structured Clinical Interview for DSM-IV Axis I Disorders (SCID-I). Current (past 30 days) and past diagnoses were cataloged separately. RESULTS:Patients ranged in age from 18 to 62 years old (M=33.9, SD=9.9); 173 (73%) were men; 197 (83%) were white. Major depression was the most prevalent mood disorder (19% current, 24% past). A minority of patients met criteria for current dysthymia (6%), past mania (1%), or past hypomania (2%). While 37 patients (16%) met criteria for current abuse of or dependence on at least one non-opioid substance (7% cocaine, 4% alcohol, 4% cannabis, 2% sedatives, 0.4% stimulants, 0.4% polydrug), 168 patients (70%) percent met criteria for past abuse of or dependence on at least one non-opioid substance (43% alcohol, 38% cannabis, 30% cocaine, 9% sedatives, 8% hallucinogens, 4% stimulants, 1% polydrug, and 0.4% other substances). CONCLUSION: Mood and substance use comorbidity is prevalent among patients seeking primary care office-based buprenorphine/naloxone treatment. The findings support the need for clinicians to assess and address these conditions.
Authors: Michael D Stein; Debra S Herman; Malyna Kettavong; Patricia A Cioe; Peter D Friedmann; Tahir Tellioglu; Bradley J Anderson Journal: J Subst Abuse Treat Date: 2010-07-03
Authors: Pier Paolo Pani; Icro Maremmani; Matteo Pacini; Francesco Lamanna; Angelo G I Maremmani; Liliana Dell'osso Journal: Eur Addict Res Date: 2010-12-17 Impact factor: 3.015
Authors: Lynn E Sullivan; Brent A Moore; Patrick G O'Connor; Declan T Barry; Marek C Chawarski; Richard S Schottenfeld; David A Fiellin Journal: Am J Addict Date: 2010 Jan-Feb
Authors: T V Parran; C A Adelman; B Merkin; M E Pagano; R Defranco; R A Ionescu; A G Mace Journal: Drug Alcohol Depend Date: 2009-08-29 Impact factor: 4.492
Authors: Pieter J Carpentier; Paul F M Krabbe; Mijke T van Gogh; Lieke J M Knapen; Jan K Buitelaar; Cor A J de Jong Journal: Am J Addict Date: 2009 Nov-Dec
Authors: Zoe M Weinstein; Hyunjoong W Kim; Debbie M Cheng; Emily Quinn; David Hui; Colleen T Labelle; Mari-Lynn Drainoni; Sara S Bachman; Jeffrey H Samet Journal: J Subst Abuse Treat Date: 2016-12-30
Authors: Declan T Barry; Tera Fazzino; Emily Necrason; Joel Ginn; Lynn E Fiellin; David A Fiellin; Brent A Moore Journal: J Addict Med Date: 2016 Sep-Oct Impact factor: 3.702